---
title: "SGLT2 Inhibitors | Intro to Pharmacology"
description: "SGLT2 inhibitors lower blood sugar by blocking kidney glucose reabsorption, and in Intro to Pharmacology you study their cardiac and renal benefits."
canonical: "https://fiveable.me/introduction-to-pharmacology/key-terms/sodium-glucose-cotransporter-2-inhibitors"
type: "key-term"
subject: "Intro to Pharmacology"
unit: "Unit 7"
---

# SGLT2 Inhibitors | Intro to Pharmacology

## Definition

Sodium-glucose cotransporter-2 inhibitors are diabetes drugs that block glucose reabsorption in the kidney, so more glucose leaves in urine. In Intro to Pharmacology, they also come up in heart failure and kidney protection.

## What It Is

Sodium-glucose cotransporter-2 inhibitors, often called SGLT2 inhibitors, are a class of drugs that lower blood glucose by changing what the kidney does with filtered sugar. Instead of letting glucose be reabsorbed from the urine back into the bloodstream, these drugs block the SGLT2 transporter in the proximal tubule, so more glucose gets excreted.

That mechanism makes them different from many older diabetes medications. They do not need insulin to work, which is why they are especially useful in type 2 diabetes, where insulin resistance is a major problem. Since the body is literally losing sugar in the urine, the drugs can also cause modest weight loss and a mild drop in blood pressure.

The class includes canagliflozin, dapagliflozin, and empagliflozin. You usually see them discussed as oral medications, and they are often chosen when a patient needs more than glucose control alone. In modern pharmacology, that matters because many patients with type 2 diabetes also have heart disease or chronic kidney disease.

A big course theme is that one drug effect can have more than one clinical payoff. By increasing glucose and sodium loss in the urine, SGLT2 inhibitors can reduce fluid burden, which helps explain why they are useful in heart failure. That same kidney-centered mechanism also ties into renal protection, especially in patients whose kidney function is already under stress.

They are not free of drawbacks, though. More sugar in the urine can raise the risk of urinary tract or genital infections, and the fluid loss can contribute to dehydration or low blood pressure. In some situations, they can also be associated with ketoacidosis, even when blood sugar is not extremely high, which is a good reminder that a drug's benefits and adverse effects often come from the same mechanism.

## Why It Matters

This term matters because Intro to Pharmacology is not just about memorizing drug names, it is about tracing how a mechanism creates both benefits and side effects. SGLT2 inhibitors are a clean example of that logic: block a transporter in the kidney, lower glucose, change fluid balance, and affect heart failure outcomes.

They also help connect different organ systems in one drug class. A medication that starts in diabetes treatment can show up again in heart failure and chronic kidney disease, so you have to think beyond one diagnosis. That is the kind of cross-system reasoning this course keeps returning to.

When you study these drugs, you are also practicing a common pharmacology skill, matching a mechanism to a clinical effect. If a question asks why a patient on empagliflozin might lose weight, have lower blood pressure, or get a urinary infection, the answer comes from the kidney transporter blocking effect. That makes SGLT2 inhibitors a useful checkpoint for mechanism based thinking.

## Connections

### Heart Failure

SGLT2 inhibitors show up in heart failure because they can reduce fluid burden and lower hospitalization risk. In this course, that makes them a good example of a drug class whose use extends beyond its original indication. When you study heart failure meds, compare them with diuretics and other agents that reduce workload or congestion.

### Renal Function

These drugs work directly in the kidney, so renal function affects whether they are appropriate and how they are monitored. Their benefits in chronic kidney disease come up because preserving kidney outcomes is part of the clinical picture, not just lowering glucose. This connection helps you think about how clearance, filtration, and nephron transport shape drug action.

### Diabetes Mellitus

SGLT2 inhibitors are a type 2 diabetes medication, so they fit into the broader topic of glucose-lowering therapy. They are especially useful when insulin independent lowering of blood sugar is helpful. In questions, they often appear alongside metformin, insulin, and other classes so you can compare mechanisms instead of just naming a drug.

### [hypotension](/introduction-to-pharmacology/key-terms/hypotension)

Because SGLT2 inhibitors increase urinary loss of glucose and water, they can contribute to lowered blood pressure. That is sometimes helpful, but it can also become a problem if a patient is already volume depleted or prone to dizziness. This is a good reminder to connect a drug's mechanism to its adverse effect profile.

## On the AP Exam

A quiz question may give you a patient with type 2 diabetes and ask which drug class lowers glucose by blocking renal reabsorption. A case question might describe weight loss, lower blood pressure, or recurrent urinary symptoms after starting therapy and ask you to connect the effect to the SGLT2 mechanism. You may also be asked to explain why these drugs can help in heart failure or chronic kidney disease, which means tracing the kidney and fluid balance effects instead of just memorizing the brand names. If the prompt asks about side effects, think dehydration, genitourinary infections, and the less common risk of ketoacidosis. The safest move is to identify the transporter, state where it acts, and connect that mechanism to the clinical outcome.

## Sodium-glucose cotransporter-2 inhibitors vs diuretics

SGLT2 inhibitors can look like diuretics because they increase urine output and lower blood pressure, but they are not classic diuretics. Their main action is blocking glucose and sodium reabsorption in the proximal tubule, while diuretics are usually grouped by where they act on renal salt handling. If a question is testing mechanism, do not call an SGLT2 inhibitor a loop or thiazide diuretic.

## Key Takeaways

- SGLT2 inhibitors block glucose reabsorption in the kidney, so more glucose leaves the body in urine.
- They are used mainly for type 2 diabetes, but they also matter in heart failure and chronic kidney disease.
- Common examples include canagliflozin, dapagliflozin, and empagliflozin.
- Their benefits come with tradeoffs, including urinary infections, dehydration, and a risk of ketoacidosis in some patients.
- In pharmacology, this class is a good example of how one transporter can affect blood sugar, fluid balance, and cardiovascular outcomes at the same time.

## FAQs

### What is sodium-glucose cotransporter-2 inhibitors in Intro to Pharmacology?

SGLT2 inhibitors are drugs that block a kidney transporter responsible for reabsorbing glucose back into the blood. In Intro to Pharmacology, you study them as type 2 diabetes medications with extra benefits in heart failure and kidney disease. The main idea is that they lower blood sugar by making the kidneys excrete glucose.

### Are SGLT2 inhibitors the same as diuretics?

No. They can cause more urination and a mild blood pressure drop, but they are not classified as classic diuretics. Their main target is the SGLT2 transporter in the proximal tubule, not the usual loop or distal salt transport pathways. That difference matters when you are asked to identify a drug by mechanism.

### Why do SGLT2 inhibitors help heart failure?

They help because they reduce fluid burden and can improve cardiovascular outcomes in selected patients. In class, this is a good example of a drug whose benefit extends beyond its original diabetes use. You should connect the kidney mechanism to lower congestion and the reduction in hospitalizations.

### What side effects should I remember for SGLT2 inhibitors?

The big ones are urinary tract or genital infections, dehydration, and low blood pressure. A less common but testable risk is ketoacidosis, which can happen even without very high glucose. If a question describes dizziness plus frequent urination, think about the drug's osmotic effect.

## Related Study Guides

- [7.3 Drugs used in the treatment of heart failure and arrhythmias](/introduction-to-pharmacology/unit-7/drugs-treatment-heart-failure-arrhythmias/study-guide/7JaRlUoLvONRlxlM)

## About This Document

Canonical Fiveable pages are available as Markdown at the same path plus `.md`.

- [llms.txt](https://fiveable.me/llms.txt): index of Fiveable's sections and URL patterns
- [llms-full.txt](https://fiveable.me/llms-full.txt): complete subject and unit listing
- [MCP server](https://fiveable.me/mcp): call Fiveable as tools instead of fetching pages (`https://fiveable.me/api/mcp`)
- [MCP server for AP teachers](https://fiveable.me/mcp/teachers): a teacher's classes, assignments and AP-rubric grading (`https://fiveable.me/api/mcp/teacher`)

## Structured Data

```json
{"@context":"https://schema.org","@graph":[{"@type":"LearningResource","@id":"https://fiveable.me/introduction-to-pharmacology/key-terms/sodium-glucose-cotransporter-2-inhibitors#resource","name":"SGLT2 Inhibitors | Intro to Pharmacology","url":"https://fiveable.me/introduction-to-pharmacology/key-terms/sodium-glucose-cotransporter-2-inhibitors","learningResourceType":"Concept explainer","educationalLevel":"AP® / High School","about":{"@id":"https://fiveable.me/introduction-to-pharmacology/key-terms/sodium-glucose-cotransporter-2-inhibitors#term"},"audience":{"@type":"EducationalAudience","educationalRole":"student"},"dateModified":"2026-07-03T02:23:32.792Z","isPartOf":{"@type":"Collection","name":"Intro to Pharmacology Key Terms","url":"https://fiveable.me/introduction-to-pharmacology/key-terms"},"author":{"@type":"Organization","@id":"https://fiveable.me/editorial#content-team","name":"Fiveable Content Team","url":"https://fiveable.me/editorial","parentOrganization":{"@id":"https://fiveable.me/#organization"},"member":[{"@type":"Person","name":"Amanda DoAmaral","sameAs":["https://www.linkedin.com/in/adoamaral"]},{"@type":"Person","name":"Becky Bahr","sameAs":["https://www.linkedin.com/in/becky-bahr-b52743132"]}]},"publisher":{"@type":"Organization","name":"Fiveable","url":"https://fiveable.me"}},{"@type":"DefinedTerm","@id":"https://fiveable.me/introduction-to-pharmacology/key-terms/sodium-glucose-cotransporter-2-inhibitors#term","name":"Sodium-glucose cotransporter-2 inhibitors","description":"Sodium-glucose cotransporter-2 inhibitors are diabetes drugs that block glucose reabsorption in the kidney, so more glucose leaves in urine. In Intro to Pharmacology, they also come up in heart failure and kidney protection.","url":"https://fiveable.me/introduction-to-pharmacology/key-terms/sodium-glucose-cotransporter-2-inhibitors","inDefinedTermSet":{"@type":"DefinedTermSet","name":"Intro to Pharmacology Key Terms","url":"https://fiveable.me/introduction-to-pharmacology/key-terms"}},{"@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What is sodium-glucose cotransporter-2 inhibitors in Intro to Pharmacology?","acceptedAnswer":{"@type":"Answer","text":"SGLT2 inhibitors are drugs that block a kidney transporter responsible for reabsorbing glucose back into the blood. In Intro to Pharmacology, you study them as type 2 diabetes medications with extra benefits in heart failure and kidney disease. The main idea is that they lower blood sugar by making the kidneys excrete glucose."}},{"@type":"Question","name":"Are SGLT2 inhibitors the same as diuretics?","acceptedAnswer":{"@type":"Answer","text":"No. They can cause more urination and a mild blood pressure drop, but they are not classified as classic diuretics. Their main target is the SGLT2 transporter in the proximal tubule, not the usual loop or distal salt transport pathways. That difference matters when you are asked to identify a drug by mechanism."}},{"@type":"Question","name":"Why do SGLT2 inhibitors help heart failure?","acceptedAnswer":{"@type":"Answer","text":"They help because they reduce fluid burden and can improve cardiovascular outcomes in selected patients. In class, this is a good example of a drug whose benefit extends beyond its original diabetes use. You should connect the kidney mechanism to lower congestion and the reduction in hospitalizations."}},{"@type":"Question","name":"What side effects should I remember for SGLT2 inhibitors?","acceptedAnswer":{"@type":"Answer","text":"The big ones are urinary tract or genital infections, dehydration, and low blood pressure. A less common but testable risk is ketoacidosis, which can happen even without very high glucose. If a question describes dizziness plus frequent urination, think about the drug's osmotic effect."}}]},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Intro to Pharmacology","item":"https://fiveable.me/introduction-to-pharmacology"},{"@type":"ListItem","position":2,"name":"Key Terms","item":"https://fiveable.me/introduction-to-pharmacology/key-terms"},{"@type":"ListItem","position":3,"name":"Unit 7","item":"https://fiveable.me/introduction-to-pharmacology/unit-7"},{"@type":"ListItem","position":4,"name":"Sodium-glucose cotransporter-2 inhibitors"}]}]}
```